Germline HNPCC gene variants have little influence on the risk for sporadic colorectal cancer

I P M Tomlinson, N E Beck, T Homfray, C J Harocopos, W F Bodmer

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) is a syndrome of inherited bowel and other cancers that has been said to account for up to 15% of all colorectal carcinomas (CRCs). HNPCC can now be diagnosed at the molecular level by detecting germline mutations in genes involved in mismatch repair. A current problem is to determine the prevalence of HNPCC mutations in colon cancer patients with limited or no family history, especially in cases of early onset. We have identified 50 cases of non-polyposis colorectal cancer without a family history of CRC or any other HNPCC cancer, who presented under the age of 45 years. Germline HNPCC variants (at the hMSH2 or hMLH1 loci) were detected in a small minority of cases (6%). The variants that we have found may be new or low penetrance mutations, or even polymorphisms. It remains possible that some of our sample have an inherited predisposition to CRC that is not caused by HNPCC mutations or by known polyposis syndromes. Our data suggest that most HNPCC mutations occur in families and have high or moderate penetrance. New or low penetrance HNPCC mutations probably do not contribute significantly to the risk of colorectal cancer in the general population and probably account for much fewer than 15% of all CRCs. Our results question whether mass population genetic screening programmes are worthwhile for diseases such as HNPCC using current technology.

Keywords: HNPCC; early onset sporadic colon cancer.

Cancer Genetics Laboratory, Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, UK

I P M Tomlinson

N E Beck

T Homfray

W F Bodmer

Colorectal Cancer Unit, Imperial Cancer Research Fund, St Mark's and Northwick Park Hospitals Trust, Watford Road, Harrow, Middlesex HA1 3UJ, UK

C J Harocopos

Correspondence to:

Dr Bodmer.

Received 13 May 1996

Revised version accepted for publication 29 August 1996

Table 1 Age distribution of the patients studied

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>No of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;20</td>
<td>1</td>
</tr>
<tr>
<td>21-25</td>
<td>3</td>
</tr>
<tr>
<td>26-30</td>
<td>4</td>
</tr>
<tr>
<td>31-35</td>
<td>6</td>
</tr>
<tr>
<td>36-40</td>
<td>22</td>
</tr>
<tr>
<td>41-45</td>
<td>16</td>
</tr>
</tbody>
</table>

Downloaded from http://jmg.bmj.com/ on May 29, 2017 - Published by group.bmj.com
any first or second degree relative was known to have benign or malignant colorectal tumours, or another HNPCC cancer, or a tumour such as breast cancer that is reportedly associated with colorectal cancer.7 Hereditary polyposis syndromes were also excluded. The following clinical data were available: age at presentation, tumour site, and Dukes's stage and grade.

Materials and methods
Peripheral blood or normal tissue was collected from each patient and DNA was extracted from these samples using standard techniques. Each exon of hMSH2 and hMLH1 (mutations in which account for >90% of HNPCC) was amplified specifically using the polymerase chain reaction (for oligonucleotide sequences and conditions, see Beck et al, in preparation; details available from authors). Single strand conformational polymorphism (SSCP) analysis was used to detect mutations, with 10% acrylamide: bisacrylamide (30:0.8) gels run at 20 mA for 18 to 24 hours and products detected by silver staining. For all cases with SSCP band shifts suggestive of mutations, two independent PCR products were sequenced alongside control samples, using the Applied Biosystems (Foster City, California) Ready Reaction Dye Terminator Cycle Sequencing kit and 377 fluorescence based, semiautomated DNA sequencer.

Results and discussion
Germline HNPCC variants were detected in three of the 50 cases (6%, table 2, fig 1). One of these variants (hMLH1 codon 77) is probably a mutation and has not been reported before in colon cancer. The other variants have been reported previously. The hMSH2 codon 322 variant was found by Liu et al8 and Foggatt et al9 and may either be a low penetrance mutation or low frequency polymorphism with normal function. The hMLH1 variant at codon 219 was reported by Liu et al8 as a polymorphism with a frequency of 13%, although it is not clear how large a sample was used to determine this frequency. Unless the hMLH1 codon 219 variant actually protects against colon cancer, our data suggest that this allele has a frequency of 1% at most and we cannot exclude a low penetrance effect on colon cancer risk. It is interesting in this regard that all the variants that we detected were missense changes from the wild type, when an excess of frameshift over missense mutations was expected from HNPCC family data10; missense mutations may have less effect on protein function and thus have reduced penetrance. Samples were not available from the parents of any of the three patients with hMSH2 or hMLH1 variants and it was not possible, therefore, to determine whether any of these people had inherited their genotypes or were new mutations. Although too few patients had variant alleles to test formally for associations with the clinical data, none of the three patients had notably extreme clinical features (table 2), such as an exceptionally early age of presentation relative to the other patients studied. Our results suggest that, in the absence of family history, patients with early onset CRC are unlikely to have germline HNPCC mutations.

Table 2  Clinicopathological features and mutations detected in the early onset cases of colorectal cancer studied

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Site</th>
<th>Stage</th>
<th>Grade</th>
<th>Gene</th>
<th>Exon</th>
<th>Codon</th>
<th>DNA change</th>
<th>Amino acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>78</td>
<td>40</td>
<td>Rectum</td>
<td>B</td>
<td>PD</td>
<td>hMLH1</td>
<td>8</td>
<td>219</td>
<td>ATC→GTG</td>
<td>Ile→Val</td>
</tr>
<tr>
<td>JM</td>
<td>40</td>
<td>Transverse</td>
<td>B</td>
<td>NR</td>
<td>hMSH2</td>
<td>6</td>
<td>322</td>
<td>GCC→GAC</td>
<td>Gly→Asp</td>
</tr>
<tr>
<td>YKY</td>
<td>37</td>
<td>Sigmoid</td>
<td>C</td>
<td>MD</td>
<td>hMLH1</td>
<td>3</td>
<td>77</td>
<td>TGT→TAT</td>
<td>Cys→Tyr</td>
</tr>
</tbody>
</table>

Three germline variants (all missense) are shown. Duke's stage (A, B, or C) is shown. Tumour grade is expressed as well, moderately, or poorly differentiated (WD, MD, PD). NR=not reported.

Figure 1  Sequences of germline variants detected (see table 2). (A) Case 78, (B) case JM, (C) case YKY.
Some inaccuracy is inevitable in our estimate of a 6% (maximum) frequency of germline HNPCC mutations in non-familial CRC which presents at ≤ 45 years of age. Three features will cause our estimate to be too low. First, we have not studied hPMS1 or hPMS2. Mutations at these loci may be poorly penetrant and more common in apparently sporadic cases of CRC than in HNPCC families, although there is evidence against this suggestion. Second, SSCP is unable to detect all mutations, with a sensitivity of 70 to 90% for small scale mutations; SSCP is not suitable, moreover, for detecting the whole exon deletions that have been reported to occur in hMSH2 and hMLH1. Third, some patients may have had a familial disease, such as attenuated APC, which went undetected. Two factors may cause our estimate of 6% to be too high. First, imperfect reporting or recording of family histories may have led some truly familial cases of HNPCC to be included in our sample. Since most patients were ascertained through surgeons with a special interest in colorectal cancer, from dedicated colorectal units, or through cancer genetics clinics, we believe that inaccuracy from this source is probably low. Second, HNPCC may have a better prognosis than other types of colorectal cancer; although not all our patients were alive at the time of this study, it is possible that early death of other cases caused HNPCC to be over-represented in our sample. Taking all factors into account, we suggest that fewer than 10% of CRC cases under 45 years of age have germline HNPCC mutations.

A previous study analysed 31 cases of CRC who presented before 35 years of age and did not have a family history fulfilling the “Amsterdam criteria”. Of these cases, 58% of the patients’ tumours had microsatellite instability; this is found in about 90% of HNPCC cancers and 10 to 20% of sporadic CRCs, and many cancers have microsatellite instability without detectable germline or somatic HNPCC mutations. Twelve patients were analysed for germline mutations at hMSH2, hMLH1, hPMS1 and hPMS2, and, of these, five (42%) had truncating mutations at hMSH2 or hMLH1; no other germline mutations were detected. In contrast, none of our 12 patients under 35 years old had mutations at hMSH2 or hMLH1 (although one case was 37 years old). Liu et al. did not study the frequency of germline HNPCC mutations in patients over 35 years of age, although microsatellite instability occurred in only 17% of the tumours from their patients in the 35 to 55 age group. The differences between our results and those of Liu et al. probably arise from the more stringent selection against family history that was used in our study. In addition, the age ranges studied may have led to even greater selection against family history in our sample than in that of Liu et al. Many unaffected, first degree relatives of patients under 35 years may have germline HNPCC mutations and go on to develop cancer in later life. Since our patients were about 10 years older on average, their parents and sibs would have had a greater chance of developing cancer, with less chance of apparent non-penetrance.

Current colonoscopic screening protocols at St Mark’s Hospital include people with a 1 in 10 risk or greater of colorectal cancer. The first degree relatives of our patients (taken as a group) would not be included in this screening programme on the basis of germline HNPCC mutations alone, because they would be at a maximum risk of about 1 in 14. We do not suggest, however, that colonoscopic screening should yet be discontinued for the relatives of early onset, sporadic cases of colon cancer. It remains possible, for example, that some of our sample have an inherited predisposition to CRC that is not caused by HNPCC mutations or by known polyposis syndrome loci. Certainly, the widespread availability of predictive genetic tests will soon allow colonoscopic screening to be targeted at the relatives of patients who do carry germline HNPCC mutations.

Our results suggest that low penetrance or new HNPCC mutations are an uncommon cause of colorectal cancer, even in patients with early onset disease. If new mutations are rare, it follows that people with germline HNPCC mutations have a high fitness. If low penetrance mutations are rare, most HNPCC cancers probably present within families. Our estimate of 10% germline HNPCC mutations in “sporadic” cases presenting under 45 years old cannot be directly extended to the general population; it is likely, however, that there is a much lower frequency of germline HNPCC mutations among the great majority of sporadic colon cancer patients, who present at over 45 years of age. The estimate that 15% of all CRCs result from HNPCC is probably much too high. It is unlikely that new or low penetrance HNPCC mutations contribute significantly to the risk of colorectal cancer in the general population. If so, mass population screening for germline defects at HNPCC loci may be of relatively little value until technological advances have made the task of mutation detection very much easier.


Germline HNPCC gene variants have little influence on the risk for sporadic colorectal cancer.
I P Tomlinson, N E Beck, T Homfray, C J Harocopos and W F Bodmer

doi: 10.1136/jmg.34.1.39

Updated information and services can be found at:
http://jmg.bmj.com/content/34/1/39

**These include:**

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/